LeMaitre Vascular (LMAT) versus The Competition Critical Review
LeMaitre Vascular (NASDAQ: LMAT) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its peers? We will compare LeMaitre Vascular to related companies based on the strength of its valuation, earnings, risk, dividends, analyst recommendations, institutional ownership and profitability.
Earnings & Valuation
This table compares LeMaitre Vascular and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|LeMaitre Vascular||$96.40 million||$23.12 million||53.74|
|LeMaitre Vascular Competitors||$2.02 billion||$430.74 million||-66.51|
LeMaitre Vascular’s peers have higher revenue and earnings than LeMaitre Vascular. LeMaitre Vascular is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
LeMaitre Vascular pays an annual dividend of $0.22 per share and has a dividend yield of 0.6%. LeMaitre Vascular pays out 31.9% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.9% and pay out 26.3% of their earnings in the form of a dividend. LeMaitre Vascular lags its peers as a dividend stock, given its lower dividend yield and higher payout ratio.
This is a breakdown of recent ratings for LeMaitre Vascular and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|LeMaitre Vascular Competitors||255||1817||3259||105||2.59|
LeMaitre Vascular currently has a consensus price target of $30.50, suggesting a potential downside of 17.75%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 5.34%. Given LeMaitre Vascular’s peers stronger consensus rating and higher probable upside, analysts plainly believe LeMaitre Vascular has less favorable growth aspects than its peers.
Risk and Volatility
LeMaitre Vascular has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, LeMaitre Vascular’s peers have a beta of 0.89, indicating that their average share price is 11% less volatile than the S&P 500.
Insider & Institutional Ownership
66.3% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 23.7% of LeMaitre Vascular shares are owned by insiders. Comparatively, 18.6% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
This table compares LeMaitre Vascular and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|LeMaitre Vascular Competitors||-327.99%||-35.86%||-12.61%|
LeMaitre Vascular peers beat LeMaitre Vascular on 9 of the 15 factors compared.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
Receive News & Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.